JUNSHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 8 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Jupiter Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on JUNS, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JUNS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 5% of US stocks
Cheaper than 96% of US stocks
Cheaper than 64% of US stocks
Higher than 78% of US stocks
Higher than 95% of US stocks
Higher than 2% of US stocks
Higher than 98% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jupiter Neurosciences, Inc. has a market value of $3.7M and an enterprise value of $2.4M.
Revenue in the twelve months to 30 June 2026: $65K. The latest quarter grew 30.0% year on year.
Net income over the same four quarters: −$9.2M, a −14220.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$7.2M.
Trailing P/E: −0.1×; forward P/E: 45.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Jupiter Neurosciences, Inc. employs 5 people — $13K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Jupiter Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Jupiter Neurosciences announced that the first patient has been dosed in its Phase 2a RESET trial of JOTROL in Parkinson’s disease. The study is evaluating safety, pharmacokinetics, and biomarkers.
Why it matters — The dosing milestone marks progress in JUNS’s Parkinson’s disease clinical study.
Jupiter Neurosciences announced it has entered into a securities purchase agreement for a registered direct offering, pricing $2.0 million through the sale of 307,692 shares of common stock. The offering was priced on August 21, 2026.
Why it matters — JUNS watchers would care because the company is raising additional capital through a registered direct offering, which affects its share count and funding position.
Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) were surging Friday morning after related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.
Why it matters — This is relevant to JUNS watchers because the surge is tied to corporate news from its biotechnology partner PharmAla, including a newly granted U.S. patent.
Jupiter Neurosciences, Inc. announced a reverse stock split, with its common stock expected to begin trading on a post-split adjusted basis on August 7, 2026.
Why it matters — A reverse stock split reduces the number of outstanding shares and typically increases the per-share price, which can affect how the stock is perceived by exchanges and investors.
Of the 1 analysts covering Jupiter Neurosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jupiter Neurosciences, Inc. 9 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Jupiter Neurosciences, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No analyst covering Jupiter Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JUNS are extrapolating price history, which says nothing about the business.
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation, central nervous system disorders, and selected rare diseases.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value". Jupiter Neurosciences announced that the first patient has been dosed in its Phase 2a RESET trial of JOTROL in Parkinson’s disease. The study is evaluating safety, pharmacokinetics, and biomarkers.
Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation, central nervous system disorders, and selected rare diseases. Its work centers on JOTROL, an enhanced oral resveratrol formulation designed for pharmaceutical use across conditions such as Parkinson’s disease, Alzheimer’s disease, and other neurological disorders. The company also operates a premium nutritional supplements segment through the Nugevia brand, which includes consumer products positioned around longevity, cognitive support, and wellness. Jupiter Neurosciences Inc. combines drug development with consumer health offerings, giving it a presence in both the biopharmaceutical and nutritional supplement markets. Headquartered in Jupiter, Florida, the company is organized around research, formulation technology, and commercial product development in the health sciences sector.
CEO Mr. Christer Rosen · 5 employees · United States · https://jupiterneurosciences.com